Johnson & Johnson: A Dividend King, But Priced Appropriately, Big Conference Slate
Johnson & Johnson is currently rated as a Hold, with its stock trading near intrinsic value. The company reported a 10% sales growth in Q1 and raised its FY 2026 guidance while extending its dividend growth streak to 64 years. However, it faces challenges from competition and market conditions, despite having a strong free cash flow yield and a solid product pipeline.
- ▪Johnson & Johnson's stock is trading near its intrinsic value with limited upside potential.
- ▪The company achieved a $450 million revenue beat in Q1, showing a 10% growth in sales.
- ▪JNJ has extended its dividend growth streak to 64 years, reflecting its commitment to returning value to shareholders.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908200-johnson-and-johnson-a-dividend-king-but-priced-appropriately-big-conference-slate"},"author":{"@type":"Person","name":"Mike Zaccardi","url":"https://seekingalpha.com/author/mike-zaccardi-cfa-cmt"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
